What is Sientra?
Founded in 2003 and headquartered in Goleta, California, Sientra operates at the intersection of medical technology and aesthetic surgery. The company specializes in the development and commercialization of high-quality silicone gel breast implants, catering to the rigorous demands of plastic surgeons and their patients. By focusing on product innovation and clinical excellence, Sientra has established itself as a critical provider within the global medical aesthetics landscape. The company's business model relies on a robust pipeline of aesthetic products, supported by a history of significant capital infusions that have enabled it to transition from a development-stage entity to a mature, enterprise-level organization capable of navigating complex regulatory and market environments.
How much funding has Sientra raised?
Sientra has raised a total of $597M across 9 funding rounds:
Series C
$65M
Stock Offering
$80.2M
Stock Offering
$66M
Debt
$20M
Stock Offering
$107.7M
Stock Offering
$108.1M
Debt
$60M
Debt
$5M
Series C (2012): $65M led by Clarus Ventures, OrbiMed, and Abingworth
Stock Issuance/Offering (2014): $80.2M, investors not publicly disclosed
Stock Issuance/Offering (2015): $66M, investors not publicly disclosed
Debt (2017): $20M backed by Silicon Valley Bank
Stock Issuance/Offering (2018): $107.7M, investors not publicly disclosed
Stock Issuance/Offering (2019): $108.1M, investors not publicly disclosed
Debt (2020): $60M supported by Deerfield Communications Inc
Debt (2020): $5M featuring PPP
Key Investors in Sientra
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and healthcare services with a deep understanding of innovation cycles.
Clarus Ventures
Blackstone Life Sciences, formerly Clarus Ventures, focuses on bringing vital medicines and technologies to market by addressing the funding gap in the life sciences sector through late-stage development support.
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that transforms cutting-edge science into novel medicines by providing capital and expertise to world-class management teams.
What's next for Sientra?
Looking ahead, Sientra is positioned to leverage its recent capital influx to further penetrate the medical aesthetics market. The company's strategic roadmap likely involves expanding its product portfolio and enhancing its distribution capabilities to meet the growing global demand for aesthetic procedures. Given the historical support from top-tier life sciences investors, Sientra is well-equipped to pursue operational efficiencies and potential market-share expansion. The focus remains on sustaining long-term growth through continued investment in clinical research and the strengthening of its commercial infrastructure, ensuring the company remains a leader in the evolving landscape of medical aesthetics.
See full Sientra company page
